Drug Trial Radar · NCT00669643
Uniform Multidrug Therapy Regimen for Leprosy Patients
Last checked: Nov 19, 2026Latest source record: Jun 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
859
Actual
Start
Feb 2007
Primary completion
Sep 2012
Study completion Dec 31, 2016
Sponsor
- Lead sponsor
- University of BrasiliaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Conselho Nacional de Desenvolvimento Científico e Tecnológico; Ministry of Science and Technology, Brazil; Ministry of Health, Brazil; Fundação Alfredo da Matta, Manaus, Brazil; Instituto de Dermatologia Dona Libania, Fortaleza, Brazil
- First posted
- Apr 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomized trial is to verify if leprosy patients, despite of their classification, can be treated with the same regimen without compromising patient cure and acceptability of the treatment. At present, patients classified as multibacillary leprosy are treated for 12 months with three drugs, and patients classified as paucibacillary leprosy are treated for 6 months with two drugs. The study is going to test a unified regimen for paucibacillary and multibacillary patients by treating leprosy patients with three drugs for 6 doses.
Conditions
- Leprosy
Interventions
PB 6 doses - Rifampicin and DapsoneDrug
Adult: 6 doses; 1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone; Children: 6 doses; 1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone
PB 6 doses - Rifampicin, Clofazimine and DapsoneDrug
Adult: 6 doses; 1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine; Children: 6 doses; 1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
MB 12 doses - Rifampicin, Clofazimine and DapsoneDrug
Adult: 12 doses; 1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine; Children: 12 doses; 1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
MB 6 doses - Rifampicin, Clofazimine and DapsoneDrug
Adult: 6 doses 1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine Children: 6 doses 1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
Primary outcomes
What the sponsor says the trial is designed to measure.
- RelapseTime frame: 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centro de Referência Nacional Alfredo da Matta - FUAM
Manaus, Amazonas, Brazil
Centro de Referência Nacional Dona Libânia - CDERM
Fortaleza, Ceará, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.